Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Feng Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7412-2455; OpenAlex author ID A5101529386. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 9

  1. Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies. Co-author DOI 10.1007/s13402-023-00874-x↗
  2. Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network. Co-author DOI 10.21037/tcr-22-709↗
  3. KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6. Co-author DOI 10.4251/wjgo.v14.i11.2157↗
  4. Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by transferring miR-100-5p. Co-author DOI 10.1016/j.tice.2021.101623↗
  5. TMEM176A acts as a tumor suppressor gene in pancreatic cancer by inhibiting ERK signaling. First author PMID 33593482↗
  6. Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression. First author DOI 10.1016/j.canlet.2018.10.039↗
  7. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis. Co-author DOI 10.1186/s12893-017-0259-1↗
  8. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Co-author DOI 10.18632/oncotarget.14745↗
  9. HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer. Co-author DOI 10.3892/or.2015.3789↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yixuan Ding · 4 shared papers, 2019–2022 · strength 0.53
  2. Fei Li · 4 shared papers, 2015–2022 · strength 0.42
  3. Wentong Mei · 3 shared papers, 2019–2022 · strength 0.38
  4. Yuchen Jia · 2 shared papers, 2021–2022 · strength 0.29
  5. Yulin Guo · 2 shared papers, 2020–2022 · strength 0.28
  6. Huizhen Huang · 1 shared paper, 2024 · strength 0.26
  7. Wen Li · 1 shared paper, 2024 · strength 0.26
  8. Fei Li · 2 shared papers, 2019–2020 · strength 0.22
  9. Ang Li · 2 shared papers, 2017 · strength 0.20
  10. Yuanxu Qu · 1 shared paper, 2022 · strength 0.16
  11. Mi Wei · 1 shared paper, 2022 · strength 0.15
  12. Fei Li · 1 shared paper, 2022 · strength 0.15
  13. Fei Li · 1 shared paper, 2021 · strength 0.13
  14. Ang Li · 1 shared paper, 2020 · strength 0.13
  15. Yecheng Wang · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.